No, E. coli is NOT susceptible to metronidazole
Metronidazole has no clinically relevant activity against E. coli or other facultative anaerobes and obligate aerobes, and should never be used to treat E. coli infections. 1
Mechanism and Spectrum of Activity
Metronidazole is exclusively active against obligate anaerobic bacteria and certain parasites. The FDA drug label explicitly states that metronidazole "is active in vitro against most obligate anaerobes but does not appear to possess any clinically relevant activity against facultative anaerobes or obligate aerobes" 1. Since E. coli is a facultative anaerobe (capable of growing with or without oxygen), it falls outside metronidazole's spectrum of activity.
The drug's mechanism requires extremely low redox potentials (around -650 mV) for activation of its nitro group, which generates toxic intermediates that damage bacterial DNA 2. These conditions exist only in obligate anaerobes, not in facultative organisms like E. coli.
Clinical Guidelines Confirm This
Multiple IDSA guidelines consistently recommend metronidazole only for anaerobic coverage, always in combination with other agents that cover gram-negative facultative organisms:
- For intra-abdominal infections: Metronidazole is combined with cefazolin, cefuroxime, ceftriaxone, cefotaxime, levofloxacin, or ciprofloxacin specifically because metronidazole alone cannot cover E. coli 3, 4
- The guidelines state antibiotics "should be active against enteric gram-negative aerobic and facultative bacilli" (which includes E. coli), with separate coverage needed for "obligate anaerobic bacilli" (covered by metronidazole) 3
Research Evidence
While laboratory studies show E. coli can be affected by metronidazole under highly artificial anaerobic conditions in vitro 5, 6, 7, animal studies demonstrate this does not translate to clinical efficacy. When tested in mouse abscess models with physiologically relevant conditions (redox potential -191 mV), metronidazole reduced E. coli counts by only 0.3-0.7 log₁₀—clinically insignificant 2, 8.
Common Pitfall
A critical error would be assuming metronidazole provides E. coli coverage in mixed infections simply because it's used in intra-abdominal or pelvic infections. Metronidazole only covers the anaerobic component (Bacteroides fragilis group, Clostridium species, etc.) in these polymicrobial infections—a separate agent is always required for E. coli 9, 3.